US 10,377,825 B2Granted

Anti-HER2 antibodies and methods of use

AssigneeGenentech, Inc.

InventorsMary Mathieu, Mark Dennis

Life of this patent

Estimating the term…

Abstract

The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.

Claims35

Dependent claims

An isolated anti-HER2 antibody comprising a HER2 binding domain comprising

i. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:57;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:62;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
53;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
ii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:57;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
iii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:58;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
iv. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:62;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
v. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:58;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
55;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
vi. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
vii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:65;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
viii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:58;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:53;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
ix. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:55;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49.

64 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/842,590Filed 14 Dec 2017 · continuation
Priority: 17 Jun 2015
Published: US 2018/0094056 A15 Apr 2018
Granted: 13 Aug 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61P 35/00
Antineoplastic agents
C07K 16/32
Against material from animals or humans: against translation products of oncogenes

Family

Application62/181,106Us provisional application · filed 17 Jun 2015
PCT/US2016/037891Parent of this continuation · filed 16 Jun 2016
US 2018/0094056 A1Pre-grant publication · published 5 Apr 2018
US 10,377,825 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.

An isolated anti-HER2 antibody comprising a HER2 binding domain comprising

i. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:57;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:62;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
53;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
ii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:57;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
iii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:58;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
iv. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:62;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
v. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:58;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
55;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
vi. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
vii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:65;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:54;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
viii. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:58;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:53;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49;
or
ix. (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:50;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:51;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:55;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:48;
and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:49.

64 more elements

Facts

Application

15/842,590Filed 14 Dec 2017 · continuation

Priority

17 Jun 2015

Published

US 2018/0094056 A15 Apr 2018

Granted

13 Aug 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61P 35/00
Antineoplastic agents
C07K 16/32
Against material from animals or humans: against translation products of oncogenes